DIAMEDICA, UAB - financials and debts

Company age: 24 y. 4 mo.

Update

DIAMEDICA - Company finances

EUR
2018
From: 2018-01-01
To: 2018-12-31
2019
From: 2019-01-01
To: 2019-12-31
2020
From: 2020-01-01
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-01
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 4,230,414 4,874,989 13,957,437 24,055,124 16,790,848 12,290,016 9,443,930 10,061,648
Profit before tax 107,512 3,127 3,279,231 5,138,574 1,340,411 1,242,653 216,946 106,380
Net profit 88,180 960 2,776,751 4,355,340 1,080,557 1,021,777 170,787 77,617
Equity 989,958 990,918 3,767,669 8,123,009 8,099,564 8,121,341 7,292,128 7,369,745
Liabilities 1,717,320 1,779,553 3,142,409 4,465,221 1,509,479 1,280,480 1,397,350 1,757,184
Non-current assets 1,119,126 1,149,109 1,625,220 3,260,825 3,196,862 2,734,109 1,929,341 2,327,795
Current assets 1,531,169 1,563,029 5,267,835 9,317,628 6,392,521 6,653,924 6,719,172 6,740,337
Total assets 2,650,295 2,712,138 6,893,055 12,578,453 9,589,383 9,388,033 8,648,513 9,068,132
Taxes paid
STI taxes - - - - - 1,916,196 767,570 985,216
Social insurance contributions - - - - - 262,480 258,904 302,186
Financial indicators
Revenue change y/y +3.3% +15.2% +186.3% +72.3% -30.2% -26.8% -23.2% +6.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 3.3% 0.0% 40.3% 34.6% 11.3% 10.9% 2.0% 0.9%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 8.9% 0.1% 73.7% 53.6% 13.3% 12.6% 2.3% 1.1%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.1% 0.0% 19.9% 18.1% 6.4% 8.3% 1.8% 0.8%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 2.5% 0.1% 23.5% 21.4% 8.0% 10.1% 2.3% 1.1%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 1.7 1.8 0.8 0.5 0.2 0.2 0.2 0.2
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. 236,116 281,250 854,539 1,408,108 853,770 604,428 440,961 440,657

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

Sales revenue

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

DIAMEDICA - Social security debts

From To Debt, €
2022-03-16 2022-03-17 1127.61

DIAMEDICA - VMI tax arrears

From To Overdue, €
2026-04-30 2026-05-25 2.92
2026-04-19 2026-04-23 2.92
2026-03-22 2026-03-27 3.32
2026-03-21 2026-03-21 15.0
2026-03-19 2026-03-20 3.18
2025-04-28 2025-05-08 0.05
2025-04-12 2025-04-16 20.36
2025-04-02 2025-04-11 1.36
2025-03-28 2025-04-01 2.08
2025-03-07 2025-03-24 2.08
2025-03-05 2025-03-06 487.63

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
DIAMEDICA, UAB (code 111768155) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €10.06M and net profit of €77.6K. Revenue increased by 6.5% year on year, but remained 18.1% below the 2023 level, showing a partial recovery after the decline in 2024. Profitability weakened over the period: net profit fell from €1.02M in 2023 to €170.8K in 2024 and €77.6K in 2025, while the profit margin declined from 8.3% to 1.8% and then to 0.8%. The balance sheet remained conservative, with total assets of €9.07M, equity of €7.37M and liabilities of €1.76M in 2025. The equity ratio was 81.3% and debt-to-equity 0.24, indicating relatively low leverage. Asset turnover was 1.11x. Based on employee metrics, revenue per employee was €457.3K and profit per employee €3.5K, pointing to strong sales productivity but limited bottom-line conversion in 2025.